<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04930627</url>
  </required_header>
  <id_info>
    <org_study_id>EMPAtia</org_study_id>
    <secondary_id>2021-000580-78</secondary_id>
    <nct_id>NCT04930627</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Empagliflozin in GSD1b Patients With Neutropenia</brief_title>
  <acronym>EMPAtia</acronym>
  <official_title>Evaluation of Efficacy and Safety of Empagliflozin in Treatment of Neutropenia in Patients With Glycogenosis Ib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Memorial Health Institute, Poland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Internal Medicine, Hypertension and Vascular Diseases, The Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Memorial Health Institute, Poland</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of neutropenia of Glycogenosis type 1b patients with empagliflozin&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Symptoms of glycogen storage disease type Ib (GSD Ib) include - among others - hypoglycemia,&#xD;
      hepatomegaly and neutropenia with concomitant neutrophil dysfunction, which results in&#xD;
      recurrent bacterial and fungal infections, and inflammatory bowel disease.&#xD;
&#xD;
      At present filgrastim is the only available drug to treat neutropenia in GSD Ib patients; it&#xD;
      stimulates neutrophil production, but doesn't restore their function. Part of GSD Ib patients&#xD;
      doesn't respond to filgrastim treatment. The latest research results showed, that neutropenia&#xD;
      and neutrophil dysfunction in GSD Ib patients are results of extensive accumulation of&#xD;
      1,5-anhydroglucitol-phosphate. Empagliflozin, a SGLT2 inhibitor, inhibits renal glucose and&#xD;
      1,5-anhydroglucitol reabsorption and is an effective and safe method of treatment of&#xD;
      neutropenia in this group of patients. Empagliflozin (Jardiance®) is a drug, which is&#xD;
      registered in Poland to treat type II diabetes in adults. The aim of our study is to evaluate&#xD;
      the efficacy and safety of neutropenia in patients with GSD Ib with empagliflozin&#xD;
      (Jardiance®).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Empaglifozin safety and tolerability measured by occurrence of adverse reactions</measure>
    <time_frame>2 years</time_frame>
    <description>Empaglifozin saftey and tolerability measured by occurrence of adverse reactions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of neutropenia treatment measured as percentage of the patients</measure>
    <time_frame>2 years</time_frame>
    <description>who achieved &gt;500 neutrophils/ml for at least 6 months with normalization of oxidative burst with decrease of bacterial and fungal infections compared to the period before study with decrease of hospitalization number with decrease of the number of defecation, gingival sores, and calprotectin average concentration in stool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosis change/withdrawal of filgrastrim</measure>
    <time_frame>2 years</time_frame>
    <description>Dosis change/withdrawal of filgrastrim</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of metabolic compensation</measure>
    <time_frame>2 years</time_frame>
    <description>measured as change of triglycerides (mg/dL), lactate (mg/dL), and uric acid (mg/dL) compared to the period before study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Glucose 6 Phosphatase Deficiency</condition>
  <arm_group>
    <arm_group_label>oral administration of Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>dosis depending on body weight: &lt;20 kg 5 mg 1x/day; 20-40 kg 2 x 5 mg; &gt;40 kg 2 x 10 mg</description>
    <arm_group_label>oral administration of Empagliflozin</arm_group_label>
    <other_name>Jardiance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Minimum age 4 weeks old female Or Male&#xD;
&#xD;
          -  GSD1b confirmed by genetic analysis with neutropenia and/or reduced respiratory burst&#xD;
&#xD;
          -  Informed consent signed by the parents/assigns, and the recipient (&gt;13 years old)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Risk of non-compliance&#xD;
&#xD;
          -  Chronic renal diseases (eGFR &lt; 60 ml/min/1,73 m2)&#xD;
&#xD;
          -  Active urinary tract infection (temporal criterion, up to recovery)&#xD;
&#xD;
          -  Participation in another clinical trial (minimum 6 months from the end of&#xD;
             participation until the date of signing the Informed Consent Form)&#xD;
&#xD;
          -  Participation in therapeutic experiment, in addition to the experimental treatment&#xD;
             with empagliflozin (minimum 12 months from the end of participation until the date of&#xD;
             signing the Informed Consent Form)&#xD;
&#xD;
          -  Pregnancy, breastfeeding&#xD;
&#xD;
          -  Allergy to Empagliflozin&#xD;
&#xD;
          -  Lack of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Children's Memorial Health Institute</name>
      <address>
        <city>Warsaw</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Magdalena Kaczor, MD</last_name>
      <phone>+48227494</phone>
      <email>mwojtylo@o2.pl</email>
    </contact>
    <investigator>
      <last_name>Dariusz Rokicki, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Memorial Health Institute, Poland</investigator_affiliation>
    <investigator_full_name>Dariusz Rokicki</investigator_full_name>
    <investigator_title>Pricipal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Glycogen Storage Disease Type I</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

